0HUZ Stock Overview
A clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Imunon, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.88 |
| 52 Week High | US$3.63 |
| 52 Week Low | US$0.66 |
| Beta | 1.96 |
| 1 Month Change | 0% |
| 3 Month Change | 4.76% |
| 1 Year Change | 4.92% |
| 3 Year Change | -81.95% |
| 5 Year Change | n/a |
| Change since IPO | -97.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HUZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -2.2% |
| 1Y | 4.9% | -11.7% | 6.8% |
Return vs Industry: 0HUZ exceeded the UK Biotechs industry which returned -11.7% over the past year.
Return vs Market: 0HUZ underperformed the UK Market which returned 6.8% over the past year.
Price Volatility
| 0HUZ volatility | |
|---|---|
| 0HUZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HUZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0HUZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 25 | Stacy Lindborg | imunon.com |
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Imunon, Inc. Fundamentals Summary
| 0HUZ fundamental statistics | |
|---|---|
| Market cap | US$12.80m |
| Earnings (TTM) | -US$18.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 0HUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HUZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.62m |
| Earnings | -US$18.62m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0HUZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 02:18 |
| End of Day Share Price | 2025/01/29 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Imunon, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Raymond Deacon | Brean Capital |
| Kumaraguru Raja | Brookline Capital Markets |